Sarah A. Holstein

6.5k total citations · 1 hit paper
139 papers, 2.8k citations indexed

About

Sarah A. Holstein is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Sarah A. Holstein has authored 139 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Molecular Biology, 63 papers in Hematology and 57 papers in Oncology. Recurrent topics in Sarah A. Holstein's work include Multiple Myeloma Research and Treatments (52 papers), Protein Degradation and Inhibitors (31 papers) and Ubiquitin and proteasome pathways (25 papers). Sarah A. Holstein is often cited by papers focused on Multiple Myeloma Research and Treatments (52 papers), Protein Degradation and Inhibitors (31 papers) and Ubiquitin and proteasome pathways (25 papers). Sarah A. Holstein collaborates with scholars based in United States, France and Italy. Sarah A. Holstein's co-authors include Raymond J. Hohl, Philip L. McCarthy, David F. Wiemer, Matthew A. Lunning, Christine Wohlford-Lenane, Huaxiang Tong, Daryl J. Murry, Staci L. Haney, Paul G. Richardson and Michelle L. Varney and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Sarah A. Holstein

130 papers receiving 2.8k citations

Hit Papers

Lenalidomide Maintenance ... 2017 2026 2020 2023 2017 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
    2017 392 citations Philip L. McCarthy, Sarah A. Holstein et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sarah A. Holstein United States 27 1.7k 1.0k 1.0k 297 289 139 2.8k
Jingxuan Pan China 38 2.7k 1.6× 1.0k 1.0× 591 0.6× 795 2.7× 236 0.8× 90 4.1k
Andrew G. Hall United Kingdom 36 2.2k 1.3× 756 0.7× 863 0.9× 400 1.3× 93 0.3× 118 4.0k
Jumei Shi China 21 1.0k 0.6× 535 0.5× 728 0.7× 170 0.6× 65 0.2× 90 2.0k
Martin E. Dowty United States 24 790 0.5× 799 0.8× 389 0.4× 129 0.4× 115 0.4× 57 3.0k
Bing Xu China 31 1.5k 0.9× 693 0.7× 386 0.4× 482 1.6× 67 0.2× 192 3.1k
Eduardo Magalhães Rego Brazil 33 2.7k 1.6× 683 0.7× 1.3k 1.3× 498 1.7× 75 0.3× 244 4.0k
Randall M. Rossi United States 17 1.8k 1.1× 678 0.7× 1.0k 1.0× 868 2.9× 101 0.3× 36 2.9k
Chris Tselepis United Kingdom 33 1.2k 0.7× 620 0.6× 720 0.7× 319 1.1× 73 0.3× 71 3.2k
H J Broxterman Netherlands 21 1.2k 0.7× 1.7k 1.7× 221 0.2× 214 0.7× 59 0.2× 27 2.4k
Babita Madan Singapore 27 1.7k 1.0× 730 0.7× 179 0.2× 219 0.7× 104 0.4× 50 2.5k

Countries citing papers authored by Sarah A. Holstein

Since Specialization
Citations

This map shows the geographic impact of Sarah A. Holstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah A. Holstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah A. Holstein more than expected).

Fields of papers citing papers by Sarah A. Holstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah A. Holstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah A. Holstein. The network helps show where Sarah A. Holstein may publish in the future.

Co-authorship network of co-authors of Sarah A. Holstein

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah A. Holstein. A scholar is included among the top collaborators of Sarah A. Holstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah A. Holstein. Sarah A. Holstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ali, Muhammad, Mamunur Rashid, Yashpal S. Chhonker, et al.. (2025). Impact of fixed phosphorus position on activity of triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Bioorganic & Medicinal Chemistry. 122. 118140–118140.
2.
Haney, Staci L., Yashpal S. Chhonker, Mamunur Rashid, Daryl J. Murry, & Sarah A. Holstein. (2025). Structure-activity relationship of isoprenoid triazole bisphosphonate-based geranylgeranyl diphosphate synthase inhibitors: Effects on pharmacokinetics, biodistribution, and hepatic transporters. Drug Metabolism and Disposition. 53(3). 100038–100038. 1 indexed citations
3.
4.
Ellithi, Moataz, Magdi Elsallab, Matthew A. Lunning, et al.. (2024). Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data. Transplantation and Cellular Therapy. 31(2). 71.e1–71.e14. 11 indexed citations
5.
Nooka, Ajay K., Jonathan L. Kaufman, César A. Rodríguez, et al.. (2024). Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study. British Journal of Haematology. 204(6). 2227–2232.
6.
Haney, Staci L., Yashpal S. Chhonker, Mamunur Rashid, et al.. (2024). Geranylgeranyl diphosphate synthase inhibition impairs osteoclast differentiation, morphology, and resorptive activity. JBMR Plus. 9(1). ziae133–ziae133. 1 indexed citations
7.
8.
Holstein, Sarah A., et al.. (2023). Geranylgeranyl diphosphate synthase: Role in human health, disease and potential therapeutic target. Clinical and Translational Medicine. 13(1). e1167–e1167. 16 indexed citations
9.
Kourelis, Taxiarchis, Radhika Bansal, Jesús G. Berdeja, et al.. (2023). Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience. Transplantation and Cellular Therapy. 29(4). 255–258. 35 indexed citations
10.
11.
Holstein, Sarah A., et al.. (2021). Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma. Drugs. 81(7). 825–840. 10 indexed citations
12.
Varney, Michelle L., et al.. (2020). Amides as bioisosteres of triazole-based geranylgeranyl diphosphate synthase inhibitors. Bioorganic & Medicinal Chemistry. 28(16). 115604–115604. 4 indexed citations
13.
Holstein, Sarah A., Zaid Al‐Kadhimi, Luciano J. Costa, et al.. (2019). Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation. 26(1). e7–e15. 12 indexed citations
14.
Richardson, Paul G., Sarah A. Holstein, Robert Schlossman, et al.. (2017). Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. Expert Opinion on Pharmacotherapy. 18(18). 1975–1985. 8 indexed citations
15.
Allen, Cheryl, et al.. (2017). Bishomoisoprenoid triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase. Bioorganic & Medicinal Chemistry. 25(8). 2437–2444. 22 indexed citations
16.
Holstein, Sarah A. & Philip L. McCarthy. (2016). Improved survival with salvage autologous stem-cell transplantation in myeloma. The Lancet Haematology. 3(7). e306–e307. 4 indexed citations
17.
Raje, Noopur, Philippe Moreau, Evangelos Terpos, et al.. (2016). Phase 2 study of tabalumab, a human anti‐B‐cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. British Journal of Haematology. 176(5). 783–795. 38 indexed citations
18.
Allen, Cheryl, et al.. (2016). A new motif for inhibitors of geranylgeranyl diphosphate synthase. Bioorganic & Medicinal Chemistry. 24(16). 3734–3741. 15 indexed citations
19.
Holstein, Sarah A. & Raymond J. Hohl. (2003). Monoterpene regulation of Ras and Ras-related protein expression. Journal of Lipid Research. 44(6). 1209–1215. 32 indexed citations
20.
Holstein, Sarah A., et al.. (1998). Phosphonate and bisphosphonate analogues of farnesyl pyrophosphate as potential inhibitors of farnesyl protein transferase. Bioorganic & Medicinal Chemistry. 6(6). 687–694. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jingxuan Pan Breakdown of academic impact, for papers by Andrew G. Hall Breakdown of academic impact, for papers by Jumei Shi Breakdown of academic impact, for papers by Martin E. Dowty Breakdown of academic impact, for papers by Bing Xu Breakdown of academic impact, for papers by Eduardo Magalhães Rego Breakdown of academic impact, for papers by Randall M. Rossi Breakdown of academic impact, for papers by Chris Tselepis Breakdown of academic impact, for papers by H J Broxterman Breakdown of academic impact, for papers by Babita Madan
Rankless by CCL
2026